KR20150099539A - 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용 - Google Patents

말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용 Download PDF

Info

Publication number
KR20150099539A
KR20150099539A KR1020157018092A KR20157018092A KR20150099539A KR 20150099539 A KR20150099539 A KR 20150099539A KR 1020157018092 A KR1020157018092 A KR 1020157018092A KR 20157018092 A KR20157018092 A KR 20157018092A KR 20150099539 A KR20150099539 A KR 20150099539A
Authority
KR
South Korea
Prior art keywords
mal
ppi
iii
dendrimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157018092A
Other languages
English (en)
Korean (ko)
Inventor
아이다 프라니아크-피에트리가
마리아 브리스제브스카
디트마르 아페란스
바르바라 크라즈네트
Original Assignee
우니베르스테트 우쯔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베르스테트 우쯔 filed Critical 우니베르스테트 우쯔
Publication of KR20150099539A publication Critical patent/KR20150099539A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A61K47/48192—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020157018092A 2012-12-06 2013-12-03 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용 Withdrawn KR20150099539A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.401934 2012-12-06
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PCT/PL2013/000154 WO2014088434A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii

Publications (1)

Publication Number Publication Date
KR20150099539A true KR20150099539A (ko) 2015-08-31

Family

ID=49955471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157018092A Withdrawn KR20150099539A (ko) 2012-12-06 2013-12-03 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용

Country Status (9)

Country Link
US (1) US20150320692A1 (cg-RX-API-DMAC10.html)
EP (1) EP2928478A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501260A (cg-RX-API-DMAC10.html)
KR (1) KR20150099539A (cg-RX-API-DMAC10.html)
AU (1) AU2013356792A1 (cg-RX-API-DMAC10.html)
CA (1) CA2896673A1 (cg-RX-API-DMAC10.html)
IL (1) IL239143A0 (cg-RX-API-DMAC10.html)
PL (1) PL234887B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088434A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) * 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
JP2016501260A (ja) 2016-01-18
PL234887B1 (pl) 2020-04-30
EP2928478A1 (en) 2015-10-14
US20150320692A1 (en) 2015-11-12
IL239143A0 (en) 2015-07-30
AU2013356792A1 (en) 2015-07-23
CA2896673A1 (en) 2014-06-12
PL401934A1 (pl) 2014-06-09
WO2014088434A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
Zhao et al. Sonodynamic therapy of NRP2 monoclonal antibody‐guided MOFs@ COF targeted disruption of mitochondrial and endoplasmic reticulum homeostasis to induce autophagy‐dependent ferroptosis
Liu et al. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways
Zanotto-Filho et al. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma
Wu et al. Regulatory mechanism of α-hederin upon cisplatin sensibility in NSCLC at safe dose by destroying GSS/GSH/GPX2 axis–mediated glutathione oxidation-reduction system
US9861659B2 (en) Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
JP2025063161A (ja) ルテリアル、並びにその分離および培養方法
Albuz et al. Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results
Ünsal et al. The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro
Su et al. Roles of PTEN gene methylation in Se-CQDs induced mitochondrial apoptosis of osteosarcoma cells
Wang et al. Endoplasmic reticulum-mitochondria dual-targeting nanoplatform suppresses cancer stemness and enhances colorectal cancer immunotherapy
Huang et al. Muscle homing peptide modified liposomes loaded with EGCG improved skeletal muscle dysfunction by inhibiting inflammation in aging mice
KR20150093216A (ko) 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-OS-Mal-III의 적용
Hamida et al. Apoptotic Responses Mediated by Nostoc‐Synthesized Silver Nanoparticles against Ehrlich Ascites Carcinoma Tumor‐Bearing Mice
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
WO2020171138A1 (ja) 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
Kim et al. Enhancement of radiation response with combined Ganoderma lucidum and Duchesnea chrysantha extracts in human leukemia HL-60 cells
Donmez et al. Investigation of the Effects of Three Different Generations of Fluoroquinolone Derivatives on Erythrocyte Fragility and Hematological Parameters in Rats
JP2004534001A (ja) 細胞に化学化合物を標的化する方法およびそれに使用する製薬学的組成物
Huang et al. Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles
CN113209122A (zh) 一种生物相容性吉西他滨给药系统及其制备方法和应用
Dąbroś et al. Vanadium compounds affect growth and morphology of human rhabdomyosarcoma cell line
Bhuyan Modification of Eryptosis, the Suicidal Erythrocyte Death, by Afatinib, Ceritinib, and Volasertib
Heydarian Study Silibinin effects on the improvement of immunogenic chemotherapy in CT26 colon cancer cell line

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150706

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid